» Articles » PMID: 39313981

Sensitive Profiling of Mouse Liver Membrane Proteome Dysregulation Following a High-Fat and Alcohol Diet Treatment

Overview
Journal Proteomics
Date 2024 Sep 24
PMID 39313981
Authors
Affiliations
Soon will be listed here.
Abstract

Alcohol consumption and high-fat (HF) diets often coincide in Western society, resulting in synergistic negative effects on liver function. Although studies have analyzed the global protein expression in the context of alcoholic liver disease (ALD) and metabolic dysfunction-associated steatotic liver disease (MASLD), none has offered specific insights on liver dysregulation at the membrane proteome level. Membrane-specific profiling of metabolic and compensatory phenomena is usually overshadowed in conventional proteomic workflows. In this study, we use the Peptidisc method to isolate and compare the membrane protein (MP) content of the liver with its unique biological functions. From mice fed with an HF diet and ethanol in drinking water, we annotate over 1500 liver proteins with half predicted to have at least one transmembrane segment. Among them, we identify 106 integral MPs that are dysregulated compared to the untreated sample. Gene Ontology analysis reveals several dysregulated membrane-associated processes like lipid metabolism, cell adhesion, xenobiotic processing, and mitochondrial membrane formation. Pathways related to cholesterol and bile acid transport are also mutually affected, suggesting an adaptive mechanism to counter the upcoming steatosis of the liver model. Taken together, our Peptidisc-based profiling of the diet-dysregulated liver provides specific insights and hypotheses into the role of the transmembrane proteome in disease development, and flags desirable MPs for therapeutic and diagnostic targeting.

References
1.
Kusuhara H, Suzuki H, Sugiyama Y . [The role of P-glycoprotein in the liver]. Nihon Rinsho. 1997; 55(5):1069-76. View

2.
Yang B, Zhang J, Sun L, Huang T, Kong Y, Li L . Mapping Novel Biomarkers of Liver Injury by Tissue Proteomic Analysis. ACS Omega. 2021; 6(10):7127-7138. PMC: 7970576. DOI: 10.1021/acsomega.1c00152. View

3.
Villeneuve J, Pichette V . Cytochrome P450 and liver diseases. Curr Drug Metab. 2004; 5(3):273-82. DOI: 10.2174/1389200043335531. View

4.
Guerra Ruiz A, Crespo J, Lopez Martinez R, Iruzubieta P, Casals Mercadal G, Lalana Garces M . Measurement and clinical usefulness of bilirubin in liver disease. Adv Lab Med. 2023; 2(3):352-372. PMC: 10197288. DOI: 10.1515/almed-2021-0047. View

5.
Isin E, Guengerich F . Complex reactions catalyzed by cytochrome P450 enzymes. Biochim Biophys Acta. 2007; 1770(3):314-29. DOI: 10.1016/j.bbagen.2006.07.003. View